Even though cooler days may seem far off, now is the best time to plan ahead for a healthy winter. One common respiratory ...

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Older adults are at increased risk of hospital admission, intensive care unit admission, and death due to respiratory syncytial virus (RSV)1 Most people experience mild RSV reinfections throughout ...

Clinicians and healthcare professionals should target adults aged 70 and over with underlying health conditions instead of the general population, when it comes to efforts to reduce spending and ...

The respiratory syncytial virus (RSV) can be particularly dangerous for older people with chronic medical conditions. Each ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...

RSV infections cause major illness, especially in infants and older adults, and rates of infection increase with age. There are now vaccines available to prevent disease caused by RSV in adults ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study ...